Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Wolkenstein

Showing results (121-130 of 220) with videos related to

Pageof 22
Sort By:
Contact Dermatitis|October 1, 1996
Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysisP Wolkenstein, O Chosidow, M L Fléchet, et al.
Skin Pharmacology and Physiology|October 26, 2005
Evaluation of skin viscoelasticity in type 1 neurofibromatosis patientsN Mimoun, N Razzouq, P Wolkenstein, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 2, 2019
Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactionsV Bérot, G Gener, S Ingen-Housz-Oro, et al.
The British Journal of Dermatology|May 27, 2010
Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysisL Valeyrie-Allanore, P Wolkenstein, L Brochard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 14, 2012
Dermatological emergencies: a comparative study of activity in 2000 and 2010A Mirkamali, S Ingen-Housz-Oro, L Valeyrie-Allanore, et al.
Pharmacogenetics|August 1, 1995
A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndromeP Wolkenstein, V Carrière, D Charue, et al.
Current Medical Research and Opinion|January 26, 2018
High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case seriesP Bardo-Brouard, C Luizard, L Valeyrie-Allanore, et al.
The British Journal of Dermatology|May 11, 2018
Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testingM El Khoury, H Assier, G Gener, et al.
Archives of Dermatology|February 15, 2001
Bleeding: a complication of neurofibromatosis 1 tumorsP Wolkenstein, M Mitrofanoff, L Lantieri, et al.
Dermatologica|January 1, 1990
Nocardia asteroides septicemia in a pemphigus patient. Successful treatment with trimethoprim-sulfamethoxazole and amikacin associationO Chosidow, P Wolkenstein, M Bagot, et al.
Pageof 22

Showing results (121-130 of 220) with videos related to

Sort By:
Pageof 22
Contact Dermatitis|October 1, 1996
Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysisP Wolkenstein, O Chosidow, M L Fléchet, et al.
Skin Pharmacology and Physiology|October 26, 2005
Evaluation of skin viscoelasticity in type 1 neurofibromatosis patientsN Mimoun, N Razzouq, P Wolkenstein, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 2, 2019
Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactionsV Bérot, G Gener, S Ingen-Housz-Oro, et al.
The British Journal of Dermatology|May 27, 2010
Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysisL Valeyrie-Allanore, P Wolkenstein, L Brochard, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 14, 2012
Dermatological emergencies: a comparative study of activity in 2000 and 2010A Mirkamali, S Ingen-Housz-Oro, L Valeyrie-Allanore, et al.
Pharmacogenetics|August 1, 1995
A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndromeP Wolkenstein, V Carrière, D Charue, et al.
Current Medical Research and Opinion|January 26, 2018
High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case seriesP Bardo-Brouard, C Luizard, L Valeyrie-Allanore, et al.
The British Journal of Dermatology|May 11, 2018
Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testingM El Khoury, H Assier, G Gener, et al.
Archives of Dermatology|February 15, 2001
Bleeding: a complication of neurofibromatosis 1 tumorsP Wolkenstein, M Mitrofanoff, L Lantieri, et al.
Dermatologica|January 1, 1990
Nocardia asteroides septicemia in a pemphigus patient. Successful treatment with trimethoprim-sulfamethoxazole and amikacin associationO Chosidow, P Wolkenstein, M Bagot, et al.
Pageof 22